Drugs / Zunsemetinib
Zunsemetinib
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06648434 | Jun 2025 → Jun 2027 expected | pancreatic ductal adenocarcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06374459 | Jan 2025 → May 2032 expected | hormone receptor-positive breast cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05511519 | Jul 2022 → Dec 2023 | psoriatic arthritis | Aclaris Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05279417 | Feb 2022 → Sep 2023 | rheumatoid arthritis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05216224 | Dec 2021 → Dec 2022 | hidradenitis suppurativa | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04524858 | Oct 2020 → Feb 2021 | cryopyrin-associated periodic syndrome | Aclaris Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04247815 | Mar 2020 → Feb 2021 | rheumatoid arthritis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04481685 Comparator | Jul 2020 → Feb 2021 | COVID-19 | University of Kansas Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zunsemetinib | “Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis” NCT06374459 ↗ |
| Known as | ATI-450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04524858 ↗ |
| Known as | CDD-450 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3704901 ↗ |
| Action | Inhibit | “small molecule MK2 inhibitor” NCT04247815 ↗ |
| Modality | Small molecule | “Oral, small molecule MK2 inhibitor” NCT04247815 ↗ |
| Route | Oral | “ATI-450 50mg oral tablet BID” NCT04247815 ↗ |